Klein, O; Lynge, J; Endahl, L; Damholt, B; Nosek, L; Heise, T (2007). "Albumin-bound basal insulin analogues (insulin detemir and NN344): Comparable time-action profiles but less variability than insulin glargine in type 2 diabetes". Diabetes, Obesity and Metabolism. 9 (3). ss. 290-9. doi:10.1111/j.1463-1326.2006.00685.x. PMID17391154.
Haahr, H; Heise, T (2014). "A review of the pharmacological properties of insulin degludec and their clinical relevance". Clinical Pharmacokinetics. 53 (9). ss. 787-800. doi:10.1007/s40262-014-0165-y. PMC4156782 $2. PMID25179915.
Wang, F; Surh, J; Kaur, M (2012). "Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review". Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. Cilt 5. ss. 191-204. doi:10.2147/DMSO.S21979. PMC3402007 $2. PMID22826637.
Nasrallah, SN; Reynolds, LR (2012). "Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?". Clinical Medicine Insights. Endocrinology and Diabetes. Cilt 5. ss. 31-7. doi:10.4137/CMED.S9494. PMC3411522 $2. PMID22879797.
Robinson, JD; Neumiller, JJ; Campbell, RK (2 Kasım 2012). "Can a New Ultra-Long-Acting Insulin Analogue Improve Patient Care? Investigating the Potential Role of Insulin Degludec". Drugs. 72 (18). ss. 2319-25. doi:10.2165/11642240-000000000-00000. PMID23145524.
Heller, S; Buse, J; Fisher, M; Garg, S; Marre, M; Merker, L; Renard, E; Russell-Jones, D; Philotheou, A; Francisco, AM; Pei, H; Bode, B; BEGIN Basal-Bolus Type 1 Trial Investigators (21 Nisan 2012). "Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial". Lancet. 379 (9825). ss. 1489-97. doi:10.1016/S0140-6736(12)60204-9. PMID22521071.
Garber, AJ; King, AB; Del Prato, S; Sreenan, S; Balci, MK; Muñoz-Torres, M; Rosenstock, J; Endahl, LA; Francisco, AM; Hollander, P; NN1250-3582 (BEGIN BB T2D) Trial Investigators (21 Nisan 2012). "Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial". The Lancet. 379 (9825). ss. 1498-507. doi:10.1016/S0140-6736(12)60205-0. PMID22521072.
Klein, O; Lynge, J; Endahl, L; Damholt, B; Nosek, L; Heise, T (2007). "Albumin-bound basal insulin analogues (insulin detemir and NN344): Comparable time-action profiles but less variability than insulin glargine in type 2 diabetes". Diabetes, Obesity and Metabolism. 9 (3). ss. 290-9. doi:10.1111/j.1463-1326.2006.00685.x. PMID17391154.
Haahr, H; Heise, T (2014). "A review of the pharmacological properties of insulin degludec and their clinical relevance". Clinical Pharmacokinetics. 53 (9). ss. 787-800. doi:10.1007/s40262-014-0165-y. PMC4156782 $2. PMID25179915.
Wang, F; Surh, J; Kaur, M (2012). "Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review". Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. Cilt 5. ss. 191-204. doi:10.2147/DMSO.S21979. PMC3402007 $2. PMID22826637.
Nasrallah, SN; Reynolds, LR (2012). "Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?". Clinical Medicine Insights. Endocrinology and Diabetes. Cilt 5. ss. 31-7. doi:10.4137/CMED.S9494. PMC3411522 $2. PMID22879797.
Robinson, JD; Neumiller, JJ; Campbell, RK (2 Kasım 2012). "Can a New Ultra-Long-Acting Insulin Analogue Improve Patient Care? Investigating the Potential Role of Insulin Degludec". Drugs. 72 (18). ss. 2319-25. doi:10.2165/11642240-000000000-00000. PMID23145524.
Heller, S; Buse, J; Fisher, M; Garg, S; Marre, M; Merker, L; Renard, E; Russell-Jones, D; Philotheou, A; Francisco, AM; Pei, H; Bode, B; BEGIN Basal-Bolus Type 1 Trial Investigators (21 Nisan 2012). "Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial". Lancet. 379 (9825). ss. 1489-97. doi:10.1016/S0140-6736(12)60204-9. PMID22521071.
Garber, AJ; King, AB; Del Prato, S; Sreenan, S; Balci, MK; Muñoz-Torres, M; Rosenstock, J; Endahl, LA; Francisco, AM; Hollander, P; NN1250-3582 (BEGIN BB T2D) Trial Investigators (21 Nisan 2012). "Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial". The Lancet. 379 (9825). ss. 1498-507. doi:10.1016/S0140-6736(12)60205-0. PMID22521072.
